DOCSLIB.ORG

India & COVID-19

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
India & COVID-19 Ø Full text online at www.ijmr.org.in Ø Submit online : http://www.journalonweb.com/ijmr India & COVID-19 (Part-IV) R.N.I. Regd. No. 2223/57 © 2021 Indian Council of Medical Research, New Delhi The Indian Journal of Medical Research Available free full text online at www.ijmr.org.in; https://ijmr.icmr.org.in/ijmr/index.aspx The Indian Journal of Medical Research is a biomedical journal with international circulation. It publishes original communications of biomedical research that advances or illuminates medical science or that educates the journal readers. It is issued monthly, in two volumes per year. All correspondence regarding submission of manuscripts, reprints, subscription etc., should be addressed to the Editor-in-Chief, The Indian Journal of Medical Research, Indian Council of Medical Research, V. Ramalingaswami Bhawan, Ansari Nagar, New Delhi-110029. (Telephone: 91-11- 26589384 Fax: 91-11-26589497; e-mail: [email protected]; [email protected]). Guidelines for contributors to the Journal are published in each issue of the Journal, also available at the Journal websites. Dr Anju Sharma Editor-in-Chief Assistant Editor: Dr Albina Arjuman Nair Editorial Assistance: Shri Man Mohan Singh, Smt. Rachna Sharma, Shri Ram Kishore Suyal Subscription rate and terms: The total number of the issues of the Journal will be 12 per year (excluding Supplements). • ` 400.00 per copy (India) • US$ 45.00 per copy (airmail) • ` 4000.00 per annum (India) • US$ 450.00 per annum (airmail) [Rate includes postal charges] No discount is available on individual, institute and agent subscription. Payment may be made by cheque/demand draft in favor of “Wolters Kluwer India Private Limited” payable at par Mumbai to below mentioned address. For more details, please visit www.ijmr.org.in/subscribe.asp Postal Address: Wolters Kluwer India Private Limited, A-202, 2nd Floor, The Qube, C.T.S. No.1498A/2, Village Marol, Andheri (East), Mumbai - 400 059, India. For subscription: Please contact Wolters Kluwer India Pvt. Ltd. at [email protected] Note : The Editor-in-Chief or the Publisher assumes no responsibility for the statements and opinion of contributors. Editorial Board Chairperson : Dr Balram Bhargava, Director-General, Indian Council of Medical Research (ICMR) and Secretary, Department of Health Research, Government of India, New Delhi Members : Dr S.S. Abdool Karim, Director, CAPRISA, University of KwaZulu-Natal, Durban, South Africa Dr C. Adithan, Former Professor, Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry Dr M.J. Albert, Professor, Department of Microbiology, Faculty of Medicine, Kuwait University, Safat, Kuwait Dr Eesh Bhatia, Professor, Department of Endocrinology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow Dr K. Dheda, Professor of Respiratory Medicine, UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa Dr S.K. Dwivedi, Professor, Department of Cardiology, King George’s Medical University, Lucknow Dr C. Dye, Director, Strategy, Policy & Information, Coordinator, Sustainable Development Goals, Office of The Director General, World Health Organization, Geneva, Switzerland Dr J.L. Excler, Senior Consultant, HIV Vaccine Clinical Development, US Military HIV Research Program, Walter Reed Army Institute of Research, Bethesda, MD, USA Dr N.K. Ganguly, Visiting Professor of Eminence, Translational Health Science and Technology Institute, Faridabad Dr Pramod K. Garg, Professor, Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi Dr. S. E. Hasnain, Former Professor & Head, Institute of Molecular Medicine, Jamia Hamdard and Honorary Professor, Indian Institute of Technology, Delhi, New Delhi Dr T. Jacob John, 439, Civil Supplies Godown Lane, Kamalakshipuram, Vellore Dr V.M. Katoch, Former Secretary, DHR & Former Director-General, Indian Council of Medical Research, New Delhi Dr Ashok Kumar, Director Professor, Department of Obstetrics and Gynaecology, Maulana Azad Medical College, New Delhi Dr Lalit Kumar, Professor & Head, Department of Medical Oncology, Dr BRA-Institute Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences, New Delhi Dr Rajeev Kumar, Professor, Department of Urology, All India Institute of Medical Sciences, New Delhi Dr A. Malhotra, Professor of Medicine, Director of Sleep Medicine, UC San Diego School of Medicine, San Diego, USA Dr K.H. Mayer, Medical Research Director, Fenway Community Health, Fenway Institute, Boston, Massachusetts, USA Dr U.K. Misra, Professor, Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow Dr V. Mohan, President, Madras Diabetes Research Foundation, Chennai Dr Vimla V. Nadkarni, President, International Association of Schools of Social Work, Tata Institute of Social Sciences, Mumbai Dr G.B. Nair, Former Ag Regional Advisor, Research Policy & Cooperation Unit, Communicable Diseases Department, World Health Organization, New Delhi Lt. Gen (Dr) Velu Nair, Group Head, Medical Sciences & Senior Consultant, Hemato-Oncology and Bone Marrow Transplant, Comprehensive Blood and Cancer Center (CBCC), Apollo Hospitals International Ltd., Gandhinagar Dr Jagat Narula, Professor of Medicine, Associate Dean for Global Health, Mount Sinai School of Medicine, New York, USA Dr M. Pai, Director, McGill Global Health Programs, Associate Director, McGill International TB Centre, McGill University, Montreal, Canada Dr Prema Ramachandran, Director, Nutrition Foundation of India, New Delhi Dr B.S. Ramakrishna, Director, Institute of Gastroenterology, SRM Institutes for Medical Sciences, Chennai Dr Graham R. Serjeant, Professor, Department of Hematology, Sickle Cell Trust (Jamaica), Jamaica Dr S.K. Sharma, Former Professor & Head, Department of Medicine, All India Institute of Medical Sciences, New Delhi Dr Harpal Singh, Professor, Centre for Biomedical Engineering, Indian Institute of Technology, New Delhi Dr K.K. Talwar, Former Chairperson, Medical Council of India, New Delhi Dr Radhika Tandon, Professor of Ophthalmology, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi Contributors are welcome to submit their manuscripts online at http://www.journalonweb.com/ijmr Announcement The Indian Journal of Medical Research invites contributions in the section on “Clinical Images”. These are high quality image(s) of a clinical entity which is unique/rare along with a short and crisp write-up describing the condition and other information available, to be submitted by contributors from medical schools and other medical research institutions. Original, high quality (300 dpi resolution) images (JPEG or TIFF) will be considered for publication after peer evaluation. Contributors kindly note: 1. There should be a title page with a clear title of 6-8 words, name(s) of contributor(s) – (not >2), with highest academic degree and affiliation(s). 2. Also provide a corresponding address and e-mail. 3. The write up should be about 100-125 words. Specific Instructions: 1. Only two authors are allowed per clinical image, at least one of the authors should be a faculty associated with the department and hospital/institute where the case was first presented and diagnosed and followed up. 2. A duly signed patient’s consent form should be obtained by the authors (but not to be uploaded along with manuscript). In case the patient is deceased, the form should be signed by a family member or a close relative of the patient. The patient’s consent form should be as per the IJMR format (can be downloaded from our website). 3. The place (Department & Institute) and period of the study (month & year when the patient was first presented) should be incorporated within the first two lines of the text. 4. The treatment strategies employed should be briefly described with outcome. 5. Follow up details of the patient should be mentioned along with the duration of follow up and outcome. 6. Undertaking and copyright transfer forms should be submitted duly signed by both the authors. Instructions for Figures & Videos: 1. Should be unique and innovative with more than one techniques involved. 2. Figures should preferably be represented as different panels of a single image (not mandatory) 3. Only CT/MRI scans, ultrasound images, Echo-cardiographs and images of ultra-sonography, endoscopy, etc. will have low preference for consideration. 4. The above may be accompanied with some other images such as • Histopathology: fluorescent micrographs, unique kinds of staining, electron micrographs, confocal microscopy, etc. • Genetic characterization techniques such as karyotyping, FISH, etc. • Cases where surgical intervention is involved should be represented with before and after images of the area under focus. • Conditions with morphological abnormalities/ physical deformities may be depicted with relevant images of the same. 5. Videos (size not exceeding 1 MB) can be uploaded, preferably in MP4 or FLV format, not exceeding 30 seconds. The contributions can be submitted online at www.journalonweb.com/ijmr. Indian J Med Res 153, January & February 2021, pp 1-240 Special Issue - India & COVID-19 (Part-IV) Guest Editors: Drs Rajesh Bhatia & Priya Abraham Contents Pages Editorial The quest continues for perfect COVID-19 vaccine Rajesh Bhatia ... 1 DOI: 10.4103/ijmr.IJMR_4165_20 Review Articles Cardiovascular manifestations of COVID-19: An evidence-based narrative review
Load more

Recommended publications
  • 23 April 2020 Update
    20 April – 23 April 2020 Contents I. Summary .............................................................................................................................1 II. European Union .................................................................................................................5 III. France ...............................................................................................................................6 IV. Italy ...................................................................................................................................7 V. Germany ............................................................................................................................8 VI. Spain ...............................................................................................................................10 VII. United Kingdom .............................................................................................................10 I. SUMMARY Number of cases: 1,009,762 (including the UK) Number of deaths: 108,223 • The EU Executive Steering Group on Shortages of Medicines Caused by Major Events held a meeting on 15 April to discuss the progress of the measures regarding availability of medicines for European patients during the COVID-19 pandemic. They also updated the Q&A document on regulatory expectations for medicinal products for human use during the COVID-19 pandemic on 20 April. On 21 April, they set-up the fast-track system to support essential medicines for COVID-19 treatment,
    [Show full text]
  • Written Evidence from Spotlight on Corruption1 (PGG18) the Public
    Written evidence from Spotlight on Corruption1 (PGG18) The Public Administration and Constitutional Affairs Committee Propriety of governance in light of Greensill inquiry Introduction The revelations arising from the Greensill affair and its fallout, coming alongside other recent and ongoing scandals, have exposed significant weaknesses in the UK system for managing conflicts of interest, lobbying, and business appointments. This is a vital opportunity to bring the UK’s standards landscape up to date, and to ensure that integrity and ethics in government are regulated in a way that befits a modern democracy. Taking action to strengthen the UK’s integrity and ethics framework would benefit the UK by helping to: build trust in politicians and government; strengthen the stability, predictability and attractiveness of the UK as a place to do business; give the UK greater credibility on the international stage in promoting democracy and good governance; and implement outstanding recommendations made by international bodies such as the UN and Council of Europe about how the UK can improve its integrity and ethics framework to prevent and tackle corruption. Key Recommendations 1. Integrity and Ethics legislation. The government should consult on the introduction of an Integrity and Ethics Bill, by the spring of 2022, which gives legislative effect to: the Law Commission’s recommendations on the introduction of a corruption in public office offence; recommendations made by international bodies to put ACOBA and the Independent Advisor on Ministerial Interests on a statutory footing; recommendations that are likely to be made by the Committee on Standards in Public Life’s Standards Matters 2.0 review in the Autumn of 2021; and recommendations likely to be made from both the Boardman review and parliamentary committees such as PACAC, including legislative reform to the Lobbying Act.
    [Show full text]
  • UK COVID-19 Vaccines Delivery Plan
    UK COVID-19 vaccines delivery plan Published 11 January 2021 Contents 1. Ministerial foreword ....................................................................................................... 3 2. Executive summary and scope ..................................................................................... 4 Supply .............................................................................................................................. 5 Prioritisation ...................................................................................................................... 6 Places ............................................................................................................................... 7 People .............................................................................................................................. 8 Tracking our progress ....................................................................................................... 9 3. Supply ......................................................................................................................... 10 Developing new vaccines ............................................................................................... 10 Ensuring vaccines meet strict safety standards for deployment ..................................... 17 Building UK manufacturing capability ............................................................................. 21 4. Prioritisation ...............................................................................................................
    [Show full text]
  • 53Rd AIIMS ANNUAL REPORT 2008–2009
    53rd AIIMS ANNUAL REPORT 2008–2009 All India Institute of Medical Sciences New Delhi 110029 Edited jointly by: Dr Sunil Chumber, Additional Professor, Department of Surgical Disciplines and Sub-Dean (Academic) Dr Tanuj Dada, Associate Professor, Dr R.P. Centre for Ophthalmic Sciences Dr Venkata Karthikeyan C, Assistant Professor, Department of Otorhinolaryngology (ENT) Dr S.K. Maulik, Professor, Department of Pharmacology Dr Raj D. Mehra, Professor, Department of Anatomy Dr Kameshwar Prasad, Professor, Department of Neurology Dr S. Rastogi, Professor, Department of Orthopaedics Dr Sushma Sagar, Assistant Professor, JPNA Trauma Centre Dr Peush Sahni, Professor, Department of Gastrointestinal Surgery Dr Pratap Sharan, Professor, Department of Psychiatry Dr D.N. Sharma, Assistant Professor, Dr BRA, Institute Rotary Cancer Hospital Dr Subrata Sinha, Professor and Head, Department of Biochemistry Dr Sanjay Kumar Sood, Assistant Professor, Department of Physiology Dr Sachin Talwar, Assistant Professor, Department of C.T.V.S. February 2010 Printed at Saurabh Printers Pvt. Ltd., A-16, Sector-IV, NOIDA (U.P.) All India Institute of Medical Sciences The All India Institute of Medical Sciences (AIIMS) was established in 1956 as an institution of national importance by an Act of Parliament with the objects to develop patterns of teaching in undergraduate and postgraduate medical education in all its branches so as to demonstrate a high standard of medical education to all medical colleges and other allied institutions in India; to bring together in one place educational facilities of the highest order for the training of personnel in all important branches of health activity and to attain self-sufficiency in postgraduate medical education.
    [Show full text]
  • COVID-19 Interim Vaccination Plan V.5 Pennsylvania
    COVID-19 Interim Vaccination Plan V.5 Pennsylvania PA COVID-19 Vaccine Task Force/PA Department of Health JANUARY 19, 2021 |VERSION 5.0 PENNSYLVANIA COVID-19 INTERIM VACCINATION PLAN Table of Contents Introduction……………………………………………………………………………………………………………………………………….2 Section 1: COVID-19 Vaccination Preparedness Planning ......................................................................... 3 Section 2: COVID-19 Organizational Structure and Partner Involvement ................................................. 4 Section 3: Phased Approach to COVID-19 Vaccination ........................................................................... 11 Section 4: Critical Populations ................................................................................................................. 17 Section 5: COVID-19 Provider Recruitment and Enrollment ................................................................... 21 Section 6: COVID-19 Vaccine Administration Capacity ........................................................................... 25 1. Health and Medical Infrastructure .......................................................................................... 25 2. Occupational Health Clinics and Closed Points of Dispensing (PODs) ..................................... 26 3. Expanded Outreach to Ensure Vaccine Access ........................................................................ 27 4. Staffing ....................................................................................................................................
    [Show full text]
  • Role and Responsibilities of the Chair of the Vaccine Taskforce
    Chair of the Vaccine Taskforce Information pack for applicants Closing date: Midday on Friday 14 May 2021 Reference no: VAC-1775 Follow us on Twitter @appointmentsdh Table of Contents Section 1: Role, responsibilities and person specification.................................................... 2 Section 2: How to apply ....................................................................................................... 4 2.1 Making an application ............................................................................................. 4 2.2 The selection process ............................................................................................. 7 2.3 Eligibility criteria ...................................................................................................... 9 2.4 How we will manage your personal information .................................................... 10 Chair of the Vaccine Taskforce - Information pack for applicants Section 1: Role and responsibilities of the Chair of the Vaccine Taskforce The Chair must enable the Vaccine Taskforce to achieve their three core objectives during the pandemic period: a. To secure access to promising vaccine/s for the UK population. b. To make provision for international distribution of vaccines. c. To strengthen the UK’s onshore capacity and capability in vaccine development, manufacturing, and supply chain to provide resilience for this and future pandemics. In recognising that the Taskforce has now been in existence for over a year, delivering these objectives
    [Show full text]
  • WHO Backs Rollout of Astrazeneca Vaccine
    this week TWINS page 423 • VACCINATING CHILDREN page 424 • BRITISH CYCLING page 427 FRANK HOERMANN/DPA/PA/ALAMY FRANK WHO backs rollout of AstraZeneca vaccine Doctors have warned of the risks associated On 16 March WHO’s chief scientist, Soumya The World Health Organization with pausing or delaying vaccination Swaminathan, said, “We do not want has urged people not to panic programmes against covid-19, as the people to panic, and we would, for the time amid reports of blood clotting number of European countries that have being, recommend that countries continue disorders in patients receiving the vaccine halted use of the Oxford University and vaccinating with AstraZeneca . So far, we AstraZeneca vaccine rose to 16. do not fi nd an association between these Denmark, Norway, Bulgaria, Iceland, events and the vaccine.” France, Germany, Italy, Spain, Portugal, The EMA said there had been 30 reports Slovenia, and Cyprus have suspended all of thromboembolic events among nearly use of the vaccine. Five other countries fi ve million people given the AstraZeneca (Austria, Estonia, Latvia, Lithuania, and vaccine in the European Economic Area. Luxembourg) have paused the use of a AstraZeneca has said 37 blood clots have LATEST ONLINE batch of a million doses of the vaccine. been reported among more than 17 million NHS and social The moves came after reports of people vaccinated in the EU and Britain. care need an extra blood clotting disorders. The Norwegian Five of the cases were deep vein thrombosis, £12bn to get back Medicines Agency said last week it was and 22 were pulmonary embolisms.
    [Show full text]
  • UKC Monthly Summary 2020 July.Odt
    UK COLUMN CONTENT – July 2020 https://www.ukcolumn.org/ukcolumn-news-archive 01st July 2020 Brian Gerrish and Mike Robinson with today's UK Column News. START – Good news: excess mortality rate falls below five-year average Leicester local lockdown – police to spot-check cars leaving the restricted zone… Government provides details without showing any evidence to support them SAGE recommended ramping up fear and turning communities against each other The Ferguson effect: a similar situation occurred with Foot & Mouth – community division This policy seems deliberate by the UK ‘government of occupation’ Increased Covid-19 testing will obviously result in an increase in reported cases Is this a trial run and normalisation of ‘City State’ powers…? CoronaVirus found in waste water as early as March 2019 in Spain The spike in excess deaths across the world happened after lockdown… 15:49 – More fear: schools, hospitals and offices told to prepare for ‘marauding’ terror attacks Mail Online: is your teen secretly struggling with depression…? Mail Online: workers’ health starts to fail at the age of 59 MSM complains about Covid-19 infodemic – the ‘wrong’ kind of information… 19:28 – David Noakes (GcMAF) contact information CoronaVirus: Upper Crust owner blames lockdown for 5,000 UK redundancies Michael Gove quotes Franklin Delano Roosevelt in Brexit comments Gove suggests that change is coming to the UK Civil Service Boris announces a ‘new deal’ - ‘the opportunity is massive’ The MainStream Media reaction to Boris…? Nothing, silence… MSM too busy
    [Show full text]
  • MCC VA COVID-19 Vaccine Provider FAQ May 2021
    COVID-19 Vaccine Provider FAQs We are actively monitoring COVID-19 vaccine developments. Below you will find helpful information and answers to some of the most frequently asked questions about COVID-19 vaccines. Magellan Complete Care has a COVID-19 Vaccine Taskforce comprised of experts, including clinicians, health plan leadership, and pharmacy network team members that meets regularly to discuss the latest developments and plan support. We are monitoring government guidance at the federal and state levels. We are taking steps to ensure you have the information you need as the information and guidelines are made available by federal and state agencies. Vaccine Development and Distribution Operation Warp Speed (OWS) was set up by the White House to coordinate efforts among federal government entities, states, and private sector partners. It aims to accelerate the testing, supply, development, and distribution of safe and effective vaccines, therapeutics, and diagnostics. There are many government agencies involved in helping with the COVID-19 pandemic. A few of the key agencies are listed below for your reference: • Food and Drug Administration (FDA) – The FDA reviews and approves or authorizes safe and effective vaccines. • Centers for Disease Control and Prevention (CDC) – The CDC is responsible for controlling the introduction and spread of infectious diseases. • Advisory Committee on Immunization Practices (ACIP) – ACIP is a committee within the CDC that provides advice and guidance on effective control of vaccine-preventable diseases in the U.S. civilian population. • National Academies of Science Engineering & Medicine (NASEM) – The National Institutes of Health (NIH) and CDC have tasked NASEM to develop a plan for equitable allocation of vaccines.
    [Show full text]
  • COVID-19 Vaccine Priority Strategy Using a Heterogenous Transmission Model Based on Maximum Likelihood Estimation in the Republic of Korea
    International Journal of Environmental Research and Public Health Article COVID-19 Vaccine Priority Strategy Using a Heterogenous Transmission Model Based on Maximum Likelihood Estimation in the Republic of Korea Youngsuk Ko 1 , Jacob Lee 2, Yeonju Kim 3, Donghyok Kwon 3 and Eunok Jung 1,* 1 Department of Mathematics, Konkuk University, Seoul 05029, Korea; [email protected] 2 Division of Infectious Disease, Department of Internal Medicine, Hallym University College of Medicine, Chuncheon 24252, Korea; [email protected] 3 Division of Public Health Emergency Response Research, Korea Disease Control and Prevention Agency, Cheongju 28159, Korea; [email protected] (Y.K.); [email protected] (D.K.) * Correspondence: [email protected] Abstract: (1) Background: The vaccine supply is likely to be limited in 2021 due to constraints in manufacturing. To maximize the benefit from the rollout phase, an optimal strategy of vaccine allocation is necessary based on each country’s epidemic status. (2) Methods: We first developed a heterogeneous population model considering the transmission matrix using maximum likelihood estimation based on the epidemiological records of individual COVID-19 cases in the Republic of Korea. Using this model, the vaccine priorities for minimizing mortality or incidence were investigated. (3) Results: The simulation results showed that the optimal vaccine allocation strategy to minimize the mortality (or incidence) was to prioritize elderly and healthcare workers (or adults) as Citation: Ko, Y.; Lee, J.; Kim, Y.; long as the reproductive number was below 1.2 (or over 0.9). (4) Conclusion: Our simulation results Kwon, D.; Jung, E. COVID-19 Vaccine support the current Korean government vaccination priority strategy, which prioritizes healthcare Priority Strategy Using a workers and senior groups to minimize mortality, under the condition that the reproductive number Heterogenous Transmission Model remains below 1.2.
    [Show full text]
  • Whole Day Download the Hansard
    Tuesday Volume 678 30 June 2020 No. 78 HOUSE OF COMMONS OFFICIAL REPORT PARLIAMENTARY DEBATES (HANSARD) Tuesday 30 June 2020 © Parliamentary Copyright House of Commons 2020 This publication may be reproduced under the terms of the Open Parliament licence, which is published at www.parliament.uk/site-information/copyright/. 133 30 JUNE 2020 134 Wendy Morton: That is a really important point. The House of Commons Prime Minister has made it clear that equitable access is an integral part of the UK’s approach to vaccine Tuesday 30 June 2020 development and distribution. Only last weekend, he emphasised how all the world’s leaders have a moral duty to ensure that covid-19 vaccines are truly available The House met at half-past Eleven o’clock to all. That is why the UK has contributed more than £313 million of UK aid to CEPI, the COVID-19 PRAYERS Therapeutics Accelerator, the Access to COVID-19 Tools (ACT) Accelerator, and the Foundation for Innovative New Diagnostics. We have also committed £1.65 billion [MR SPEAKER in the Chair] to Gavi over five years to strengthen immunisation for Virtual participation in proceedings commenced (Order, vaccine preventable disease in vulnerable countries. 4 June). Andrew Jones: Around the world, there are more than [NB: [V] denotes a Member participating virtually.] 100 programmes to develop a coronavirus vaccine. Can my hon. Friend confirm that our global diplomatic presence is assisting UK companies and universities to Oral Answers to Questions participate in those programmes, basically by using their local networks to highlight the significant expertise that the UK can contribute, but also vice versa to identify where those contacts can contribute to UK-based FOREIGN AND COMMONWEALTH OFFICE programmes, because this is truly a global effort? The Secretary of State was asked— Wendy Morton: Yes, our overseas network is working actively around the globe, particularly through our Covid-19 Vaccine world-leading science and innovation network.
    [Show full text]
  • Nominations for Padma Awards 2011
    c Nominations fof'P AWARDs 2011 ADMA ~ . -­ - , ' ",::i Sl. Name';' Field State No ShriIshwarappa,GurapJla Angadi Art Karnataka " Art-'Cinema-Costume Smt. Bhanu Rajopadhye Atharya Maharashtra 2. Designing " Art - Hindustani 3. Dr; (Smt.).Prabha Atre Maharashtra , " Classical Vocal Music 4. Shri Bhikari.Charan Bal Art - Vocal Music 0, nssa·' 5. Shri SamikBandyopadhyay Art - Theatre West Bengal " 6: Ms. Uttara Baokar ',' Art - Theatre , Maharashtra , 7. Smt. UshaBarle Art Chhattisgarh 8. Smt. Dipali Barthakur Art " Assam Shri Jahnu Barua Art - Cinema Assam 9. , ' , 10. Shri Neel PawanBaruah Art Assam Art- Cinema­ Ii. Ms. Mubarak Begum Rajasthan i", Playback Singing , , , 12. ShriBenoy Krishen Behl Art- Photography Delhi " ,'C 13. Ms. Ritu Beri , Art FashionDesigner Delhi 14. Shri.Madhur Bhandarkar Art - Cinema Maharashtra Art - Classical Dancer ­ IS. Smt. Mangala Bhatt Andhra Pradesh Kathak Art - Classical Dancer ­ 16. ShriRaghav Raj Bhatt Andhra Pradesh Kathak : Art - Indian Folk I 17., Smt. Basanti Bisht Uttarakhand Music Art - Painting and 18. Shri Sobha Brahma Assam Sculpture , Art - Instrumental 19. ShriV.S..K. Chakrapani Delhi, , Music- Violin , PanditDevabrata Chaudhuri alias Debu ' Art - Instrumental 20. , Delhi Chaudhri ,Music - Sitar 21. Ms. Priyanka Chopra Art _Cinema' Maharashtra 22. Ms. Neelam Mansingh Chowdhry Art_ Theatre Chandigarh , ' ,I 23. Shri Jogen Chowdhury Art- Painting \VesfBengal 24.' Smt. Prafulla Dahanukar Art ~ Painting Maharashtra ' . 25. Ms. Yashodhara Dalmia Art - Art History Delhi Art - ChhauDance­ 26. Shri Makar Dhwaj Darogha Jharkhand Seraikella style 27. Shri Jatin Das Art - Painting Delhi, 28. Shri ManoharDas " Art Chhattisgarh ' 29. , ShriRamesh Deo Art -'Cinema ,Maharashtra Art 'C Hindustani 30. Dr. Ashwini Raja Bhide Deshpande Maharashtra " classical vocalist " , 31. ShriDeva Art - Music Tamil Nadu Art- Manipuri Dance 32.
    [Show full text]